These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2319559)

  • 1. Novel quinuclidine-based ligands for the muscarinic cholinergic receptor.
    Saunders J; Cassidy M; Freedman SB; Harley EA; Iversen LL; Kneen C; MacLeod AM; Merchant KJ; Snow RJ; Baker R
    J Med Chem; 1990 Apr; 33(4):1128-38. PubMed ID: 2319559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel series of non-quaternary oxadiazoles acting as full agonists at muscarinic receptors.
    Freedman SB; Harley EA; Patel S; Newberry NR; Gilbert MJ; McKnight AT; Tang JK; Maguire JJ; Mudunkotuwa NT; Baker R
    Br J Pharmacol; 1990 Nov; 101(3):575-80. PubMed ID: 2076477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and muscarinic activity of quinuclidinyl- and (1-azanorbornyl)pyrazine derivatives.
    Street LJ; Baker R; Book T; Reeve AJ; Saunders J; Willson T; Marwood RS; Patel S; Freedman SB
    J Med Chem; 1992 Jan; 35(2):295-305. PubMed ID: 1732546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological activity of 1,2,4-oxadiazole derivatives: highly potent and efficacious agonists for cortical muscarinic receptors.
    Street LJ; Baker R; Book T; Kneen CO; MacLeod AM; Merchant KJ; Showell GA; Saunders J; Herbert RH; Freedman SB
    J Med Chem; 1990 Oct; 33(10):2690-7. PubMed ID: 2213823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent anti-muscarinic activity in a novel series of quinuclidine derivatives.
    Starck JP; Talaga P; Quéré L; Collart P; Christophe B; Lo Brutto P; Jadot S; Chimmanamada D; Zanda M; Wagner A; Mioskowski C; Massingham R; Guyaux M
    Bioorg Med Chem Lett; 2006 Jan; 16(2):373-7. PubMed ID: 16275087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetrahydropyridyloxadiazoles: semirigid muscarinic ligands.
    Showell GA; Gibbons TL; Kneen CO; MacLeod AM; Merchant K; Saunders J; Freedman SB; Patel S; Baker R
    J Med Chem; 1991 Mar; 34(3):1086-94. PubMed ID: 2002451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors.
    Hargreaves RJ; McKnight AT; Scholey K; Newberry NR; Street LJ; Hutson PH; Semark JE; Harley EA; Patel S; Freedman SB
    Br J Pharmacol; 1992 Oct; 107(2):494-501. PubMed ID: 1422595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor.
    Orlek BS; Blaney FE; Brown F; Clark MS; Hadley MS; Hatcher J; Riley GJ; Rosenberg HE; Wadsworth HJ; Wyman P
    J Med Chem; 1991 Sep; 34(9):2726-35. PubMed ID: 1895293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and pharmacology of quinuclidine derivatives as M2-selective muscarinic receptor ligands.
    Böhme TM; Keim C; Dannhardt G; Mutschler E; Lambrecht G
    Bioorg Med Chem Lett; 2001 May; 11(9):1241-3. PubMed ID: 11354386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does rigidity in structure of muscarinic agonists and antagonists reflect drug specificity?
    Fisher A; Abraham S; Lachman C; Lass Y; Akselrod S; Akerman E; Cohen S
    Monogr Neural Sci; 1980; 7():41-54. PubMed ID: 7231438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
    Bromidge SM; Brown F; Cassidy F; Clark MS; Dabbs S; Hadley MS; Hawkins J; Loudon JM; Naylor CB; Orlek BS; Riley GJ
    J Med Chem; 1997 Dec; 40(26):4265-80. PubMed ID: 9435896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel muscarinic acetylcholine receptor hybrid ligands embedding quinuclidine and 1,4-dioxane fragments.
    Del Bello F; Bonifazi A; Giorgioni G; Petrelli R; Quaglia W; Altomare A; Falcicchio A; Matucci R; Vistoli G; Piergentili A
    Eur J Med Chem; 2017 Sep; 137():327-337. PubMed ID: 28609709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
    Dunbar PG; Durant GJ; Rho T; Ojo B; Huzl JJ; Smith DA; el-Assadi AA; Sbeih S; Ngur DO; Periyasamy S
    J Med Chem; 1994 Aug; 37(17):2774-82. PubMed ID: 8064804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease.
    Fisher A; Brandeis R; Karton I; Pittel Z; Gurwitz D; Haring R; Sapir M; Levy A; Heldman E
    J Pharmacol Exp Ther; 1991 Apr; 257(1):392-403. PubMed ID: 2019998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-Heteroarylquinuclidin-2-ene derivatives as muscarinic antagonists: synthesis, structure-activity relationships and molecular modelling.
    Nordvall G; Nilsson BM; Sundquist S; Johansson G; Glas G; Nilvebrant L; Hacksell U
    Prog Brain Res; 1996; 109():141-5. PubMed ID: 9009700
    [No Abstract]   [Full Text] [Related]  

  • 16. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.
    Watson M; Roeske WR; Yamamura HI
    J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-(2-Benzofuranyl)quinuclidin-2-ene derivatives: novel muscarinic antagonists.
    Nordvall G; Sundquist S; Johansson G; Glas G; Nilvebrant L; Hacksell U
    J Med Chem; 1996 Aug; 39(17):3269-77. PubMed ID: 8765510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimuscarinic 3-(2-furanyl)quinuclidin-2-ene derivatives: synthesis and structure-activity relationships.
    Johansson G; Sundquist S; Nordvall G; Nilsson BM; Brisander M; Nilvebrant L; Hacksell U
    J Med Chem; 1997 Nov; 40(23):3804-19. PubMed ID: 9371246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
    Watson M; Yamamura HI; Roeske WR
    J Pharmacol Exp Ther; 1986 May; 237(2):411-8. PubMed ID: 3754580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.
    Loudon JM; Bromidge SM; Brown F; Clark MS; Hatcher JP; Hawkins J; Riley GJ; Noy G; Orlek BS
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1059-68. PubMed ID: 9399977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.